For the study, Morgans and her coauthors evaluated data for 284 patients. Of the cohort, 37% had known PSADT and 63% had unknown PSADT. More patients with known PSADT had characteristics of more ...

Initial data from the TALAPRO-2 trial were shared in 2023, showing that the combination of enzalutamide plus talazoparib extended radiographic progression-free survival (rPFS) vs enzalutamide alone.

“For someone that might be looking at getting into sacral neuromodulation, and has had some reluctance in the past, this does simplify the procedure somewhat," says Colin Goudelocke, MD. Six-month ...

An expert discusses how non–muscle invasive bladder cancer (NMIBC) treatment involves evolving delivery systems, transitioning from traditional systemic and intravesical approaches to advanced ...

“Interestingly, the patients that were more likely to follow-up were those patients that were seen and established within our urology clinic,” says Christina B. Ching, MD. In this interview, Christina ...